HOTH vs HUMA

Hoth Therapeutics, Inc. vs Humacyte, Inc. — Valuation Comparison 2026

HOTH

Biotechnology
Hoth Therapeutics, Inc.
Quality
3.9
out of 10
Value Trap
12
SAFE
Price
$1.36
Last close
Models
7/13
Active
VS

HUMA

Biotechnology
Humacyte, Inc.
Quality
3.5
out of 10
Value Trap
36
LOW
Price
$1.28
Last close
Models
5/13
Active

Model-by-Model Comparison

ModelType HOTH Fair ValueHOTH Upside HUMA Fair ValueHUMA Upside
Bayesian DCF Intrinsic $0.48 -64.7% $0.35 -73.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.68 -50.0%
Dynamic NAV Asset-Based $0.85 -37.2% $0.36 -72.2%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for HOTH vs HUMA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

HOTH vs HUMA — Which Stock Is More Undervalued?

HOTH scores higher with a 3.9/10 quality rating vs HUMA's 3.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Hoth Therapeutics, Inc. (HOTH) and Humacyte, Inc. (HUMA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

HOTH currently trades at $1.36 with a QOC of 3.9/10, while HUMA trades at $1.28 with a QOC of 3.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).